A new multicenter, international study suggests that people who have early-stage triple-negative breast cancer (TNBC) and high levels of immune cells within their tumors may have a lower risk of ...

For patients with early-stage triple-negative breast cancer (TNBC), finishing chemotherapy and surgery should feel like the end of the hardest chapter. But for many, it marks the beginning of a ...

Fact checked by Nick Blackmer Triple-negative breast cancer (TNBC) care has advanced in recent years, offering hope for ...

In an analysis of patients with early-stage triple-negative breast cancer (TNBC), detection of tissue-free circulating tumor DNA (ctDNA) during surveillance strongly predicted recurrence, with a ...

In this study, researchers evaluated the validity and prognostic value of tissue-free ctDNA analysis among 159 patients with early TNBC who were part of the phase 2 cTRAK trial.

Patient-derived xenografts (PDX) may accurately predict early recurrence and survival outcomes in triple negative breast cancer (TNBC), offering a potential tool for tailoring treatment strategies to ...

A small clinical trial shows promising results for patients with triple-negative breast cancer who received an investigational vaccine designed to prevent recurrence of tumors. Conducted at Washington ...

Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

ROCHESTER, Minn. — A new multicenter, international study suggests that people who have early-stage triple-negative breast cancer (TNBC) and high levels of immune cells within their tumors may have a ...